Full-Time

Head of Medical Affairs

Posted on 11/23/2025

CSL

CSL

10,001+ employees

Develops and delivers biotherapies and vaccines

No salary listed

Maidenhead, UK

In Person

Category
Medical, Clinical & Veterinary (1)
Requirements
  • A degree in the Sciences, such as a Medical Doctor, Doctor of Philosophy, Doctor of Pharmacy, Doctor of Public Health, or Doctor of Science
  • Minimum 7-10 years’ experience in the pharmaceutical industry
  • Experience in driving the medical strategy of products with excellent working knowledge of regulatory affairs, pharmacovigilance, research and clinical development programs
  • Extensive experience with industry promotional codes and procedures
  • Knowledge and understanding of drug development processes with specific expertise on vaccines
  • Superior technical medical knowledge regarding influenza vaccines and pandemic vaccines
  • Strong ability to critically review business plans and make recommendations
  • Advanced scientific and/or medical degree with relevant or related experience preferably in vaccinology, infectious disease epidemiology, vaccine clinical development and medical affairs
  • At least 10 years of experience in medical affairs scientific activities
  • Ability to interact with key opinion leaders and government officials dealing with immunization programs/vaccine policy and vaccine recommendations at the highest levels
  • Demonstrated experience in leading a matrixed team
  • Demonstrated ability to lead across diverse cultures and geographies
  • Significant cross-functional leadership/management experience with demonstrated excellence in leadership behaviour
  • Knowledge of immunization programs and an established network of key opinion leaders within the vaccine field and relationships with established academic institutions
  • Knowledge of the commercial and environmental issues that drive development vaccine projects
  • Demonstrated ability in the design, initiation, and reporting of clinical studies as part of an integrated clinical plan
  • Proven ability to influence and succeed through others and to form excellent relationships with key cross-functional stakeholders
  • Documented ability to take a relevant vaccine or vaccine-preventable disease project from start to end including conception, design, protocol, analytic plan, implementation, analysis, and reporting and interpretation of results
  • Ability to review, evaluate, interpret, and present complex data; understand the emerging safety and efficacy profile of CSL Seqirus Influenza vaccines
  • Understand the critical data elements related to assessing the public health value of Influenza vaccines, ability to oversee or conduct public health analyses of Influenza vaccine impact, and ability to interpret data and data limitations for both CSL Seqirus and competitor Influenza vaccines
  • Excellent verbal and written communication skills including scientific writing skills
  • Proven ability to influence and succeed through others and to form excellent relationships with key cross-functional stakeholders
  • Demonstrated strong work ethic, and proven track record of delivering high quality within timelines
  • Values and behaviours consistent with CSL Seqirus
  • Ability to coach, develop and direct those that report to Director of Medical Affairs
Responsibilities
  • Develop and execute the UK and Ireland medical strategic plans for Influenza and other vaccines and work with the Regional Head of Medical Affairs to ensure implementation of the medical affairs strategy plan
  • Provide quality and strategic medical input to achieve medical objectives for Influenza and other vaccines in UK and Ireland
  • Engage with external experts, research partners, public health and government stakeholders to promote CSL Seqirus scientific platform and enhance company reputation
  • Provide medical governance into decision-making and issue management and external communications
  • Ensure local pharmacovigilance compliance
  • Provide medical leadership for CSL Seqirus Vaccine Portfolio
  • Identify key opinion leaders in infectious disease and cultivate a nationwide network of influenza experts for scope areas; establish medical team as conduit for credible scientific information between KOLs, investigators and CSL Seqirus internal functions
  • Maintain professional relationships with medical and public health experts, government officials, immunisation advisory committees such as JCVI, partner companies; engage with leading KOLs for advisory boards and insights into unmet patient needs
  • Represent CSL Seqirus at scientific and medical forums, including medical education forums, scientific roundtables, congresses, and symposia
  • Plan, design and manage or participate in medical Advisory Boards including working with vendors in support of medical affairs strategies
  • Develop and design the UK and Ireland medical strategic plans for Influenza and other vaccines and work with the Regional Head of Medical Affairs to implement the strategy
  • Provide medical leadership for scientific communications including core scientific statements, standard responses, Phase IV plans, medical symposia, medical education activities and publications
  • Provide medical input and advice into development of commercial campaigns and ensure timely sign-off for Medical Copy Clearance for all CSL Seqirus vaccines in UK and Ireland
  • Scientific oversight of UK and Ireland Phase 4 studies and collaboration with external experts and cross-functional team to complete studies to timelines and budget
  • Serve as authoritative source of clinical expertise on CSL Seqirus vaccines including interaction with regulatory agencies for clinical product maintenance

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Simplify Jobs

Simplify's Take

What believers are saying

  • HEMGENIX gene therapy sustains 37% factor IX levels through four years post-2025 data.
  • KOSTAIVE self-amplifying mRNA COVID vaccine approved by EC February 2025.
  • VarmX $2.2B acquisition option expands bleeding disorder pipeline in 2026.

What critics are saying

  • Seqirus separation triggers $500M charges and 14% revenue loss from Pentagon mandate scrap.
  • Grifols opens 20 plasma centers by 2027, eroding CSL Behring's immunoglobulin share.
  • Novartis Fabhalta displaces CSL Vifor's $1.5B nephrology revenues within 12 months.

What makes CSL unique

  • CSL Behring leads plasma-derived therapies for haemophilia and immunodeficiencies.
  • CSL Seqirus dominates influenza vaccines with global production scale.
  • CSL Vifor specializes in iron deficiency and nephrology treatments post-2022 acquisition.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at CSL who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Company News

USA Herald
Sep 16th, 2025
CSL to Acquire VarmX in $2.2B Biotech Breakthrough Deal - USA Herald

In a high-stakes move that could reshape emergency medicine, global biotech giant CSL has struck an exclusive option agreement to acquire VarmX, a Netherlands-based biotech, in a deal valued at up to $2.2 billion. The announcement, made Tuesday by EQT Life Sciences, which counts VarmX in its portfolio, underscores just how valuable the Dutch company’s CSL to acquire VarmX in a $2.2B deal, backing breakthrough bleeding drug VMX-C001 with full trial funding.

CSL
Sep 16th, 2025
CSL Limited Celebrates 25 Years on the ASX

Global biotechnology leader, CSL, celebrated the Company’s 25th Anniversary of listing on the Australian Securities Exchange (ASX), commemorating the occasion with a ceremonial bell ring at...

Stock Titan
Aug 1st, 2025
Automated Logic Acquires Control Solutions Ltd.

Automated Logic – Canada, Ltd. (ALC), part of Carrier Global Corporation, has acquired Control Solutions, Ltd. (CSL), an independent provider of building-automation systems in Coquitlam, British Columbia. This acquisition establishes ALC's first field office in Vancouver, expanding its presence in Western Canada and enhancing its ability to deliver intelligent building solutions in high-growth sectors across British Columbia.

PharmiWeb.com
Apr 14th, 2025
First Patient Treated With Hemgenix® (Etranacogene Dezaparvovec) Gene Therapy For Haemophilia B In Austria

Vienna, Austria – 9 April 2025 - CSL Behring Austria today announced that the first haemophilia B patient in Austria was treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at the Comprehensive Care Center of the University Hospital of Medicine Vienna.HEMGENIX® is the first one-time gene therapy approved in Europe for the treatment of adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1“It is a great opportunity for people with hemophilia B to live a symptom-free life for many years,” explains hematologist Univ.-Prof. Priv.-Doz. Dr Cihan Ay from the Medical University of Vienna, University Clinic for Internal Medicine I Clinical Department for Hematology and Hemostaseology."For the community of affected patients and their families, this represents an enormously significant milestone: the ability to treat hemophilia with gene therapy, and the fact that this option is now available in Austria, is something our community has been eagerly anticipating and hoping for over decades," says Thomas Schindl, MA, Chairman of the Austrian Hemophilia Society (ÖHG)."We are proud and grateful to offer haemophilia B patients in Austria a treatment option that has the potential to transform their lives," said Dr Beate Natmessnig, Managing Director of CSL Behring Austria. "This achievement is the result of outstanding regional and national collaboration among all parties involved and is a strong testament to Austria's innovative capabilities."HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022

PharmiWeb.com
Apr 3rd, 2025
Csl Behring And Gkv-Spitzenverband Agree On Reimbursement Price For Hemgenix® – Europe'S First Gene Therapy For Haemophilia B

Marburg, Germany, 2 April 2025 – CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX®. This agreement marks the availability of the first gene therapy approved in Europe for haemophilia B under an innovative, national, success-based reimbursement model, being implemented for the first time in Germany.HEMGENIX® represents significant progress in the treatment of haemophilia B. The aim of this one-time gene therapy is to eliminate the need for regular factor IX infusions, thereby offering patients the possibility of more freedom from prophylaxis and significantly improving their quality of life.1-4 This development not only provides substantial relief for those affected but also has the potential to reduce long-term costs for the healthcare system.‘The performance-based payment model at national level which was agreed with the GKV-Spitzenverband is unique in Germany. It addresses key reimbursement challenges, such as the question of long-term efficacy, which is inherent for any one-time therapy. Reimbursement is linked to treatment success of the individual patient,’ explains Stefan Neudoerfer, CSL Behring's chief negotiator in Germany.Moreover, this reimbursement model reflects the high therapeutic and innovative value of HEMGENIX® and sets new standards for integrating innovative gene therapies into the German healthcare system.‘The agreement on the reimbursement price of HEMGENIX® is a decisive step for the care of people with haemophilia B in Germany. It enables access to a groundbreaking therapy and recognises the long-term medical and economic benefits of gene therapy,’ explains Christian Wieszner, Managing Director of CSL Behring Germany.With this agreement, CSL Behring is underlining its commitment to innovative therapies that sustainably improve the lives of patients

INACTIVE